Arno Therapeutics Inc ARNI:Over The Counter Mkt

*Data is delayed | Exchange | USD
Last | 04/23/24 EDT
0.0003UNCH (UNCH)
52 week range
0.00 - 0.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0003
  • 52 Week High0.00
  • 52 Week High Date04/23/24
  • 52 Week Low0.00
  • 52 Week Low Date03/01/24

Key Stats

  • Market Cap14,804.926
  • Shares Out49.35M
  • 10 Day Average Volume3,500
  • Dividend-
  • Dividend Yield-
  • Beta2.39
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.0003
  • 52 Week High0.00
  • 52 Week High Date04/23/24
  • 52 Week Low0.00
  • 52 Week Low Date03/01/24
  • Market Cap14,804.926
  • Shares Out49.35M
  • 10 Day Average Volume3,500
  • Dividend-
  • Dividend Yield-
  • Beta2.39
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.43
  • P/E (TTM)-0.00
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-11.055M
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-0.09%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Arno Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Arno Therapeutics, Inc. is an early-stage company focused on developing products for the treatment of cancer and other life threatening diseases. The Company's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various...
Arie Belldegrun M.D.
Chairman of the Board
Alexander Zukiwski M.D.
Chief Executive Officer, Chief Medical Officer, Vice President, Director
Address
200 Route 31 North, Suite 104
Flemington, NJ
08822
United States